FG’s Biovaccines Nigeria Ltd to Commence Vaccine Production in Q2 2023

Biovaccines Nigeria Limited (BVNL)a joint venture between the Federal Government of Nigeria (FGN) and mayo and baker nigeria plcVaccine production is scheduled to start before the second quarter of 2023.

This was revealed by the Managing Director of May & Baker Nigeria Plc, Mr. Patrick Ajah, on Wednesday in Lagos.

He added that the company already has a site in Ota where the factory will be built.

More details: Mr. Ajah said that the FEC approved the first part of the Biovaccines MoU on September 14, 2022 with the Federal Ministry of Health for the supply of routine immunization vaccines.

  • “This is the first/big step towards vaccine production in Nigeria as it allows Biovaccines to begin engagement with chosen technology transfer partners and subsequently start design and construction of the greenfield project.
  • “We are optimistic that the groundbreaking ceremony for the vaccine production plant will take place before the second quarter of 2023.
  • “This big event will happen before the second quarter of 2023, it will be an important announcement. We already have a site in Ota where the factory will be built.

He added that BVNL is waiting for some of these processes to kick in, adding that they are also talking to partners, financial partners and technology partners.

The news continues after this announcement.

Factory Features: Ajah said that when the factory opens in the first quarter of 2023, it will have the capacity to meet current water demands with room for improvement.

  • “We will also be making significant investments in new machines for our paracetamol plant and Pharmacentre to ensure we can meet our growing demand for existing and new products.
  • “We have made plans for significant growth in our business in 2023 during the current year, having obtained board approval for the 2023 budget that captures the realities of an election year and plans to mitigate its potential impact on the business. ”.

He added that BVNL would continue to invest in research and development to identify and introduce innovative products that would address the health challenges of Nigerians.

What you should know: Nairametry previously reported This year the World Health Organization said Biovaccines Nigeria Limited (BVNL) of Nigeria and 14 other manufacturers in Africa will receive support from the mRNA technology transfer programme.

The news continues after this announcement.

Leave a Comment